Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline

Funding Amount:
Adcendo has secured $135 million in funding to support its antibody-drug conjugate (ADC) pipeline12.

Investor:
The funding is backed by Novo Holdings, a significant investor in the biotech sector12.

Purpose:
The funds will be used to launch several ADC candidates into clinical trials, advancing Adcendo's pipeline12.

Previous Deals:
Adcendo has previously licensed a Multitude anti-TF ADC in a deal valued over $1 billion4.

Series B Funding:
This $135 million funding is part of Adcendo's Series B round, indicating significant investment in the company's ADC technology3.

Sources:

1. https://www.fiercebiotech.com/biotech/novo-holdings-backed-adcendo-secures-135m-adc-pipeline

2. https://biotechjobs.io/2024/11/25/novo-holdings-backed-adcendo-secures-135m-for-adc-pipeline/

3. https://www.newsnow.com/us/?search=%22Adcendo%22&lang=en&searchheadlines=1

4. https://www.cafepharma.com/category/news-tags/companies/adcendo